Mayo Clinic Laboratories > Oncology > Colorectal & GI

colorectal and gastrointestinal cancer

Meaningful answers to assess risk and guide treatment

Among types of colorectal cancer, which is the third most common form of cancer in the U.S., sporadic cancers are more common. Hereditary colon cancers, however, are also frequent, and identification of inherited causes affects screening recommendations both for the individual and family members.

The results and interpretations from our laboratories provide clinically actionable results to guide treatment selection, ensuring every patient receives the medication most appropriate for care. In addition to guiding treatment, our testing also assesses risk for developing hereditary cancer syndrome.

Hereditary colon cancer Hereditary colon cancer
HEREDITARY COLON CANCER

Our evaluations for Lynch syndrome include germline evaluations and testing for microsatellite instability status and defective mismatch repair.

Next-generation sequencing Next-generation sequencing
next-generation sequencing

Our next-generation sequencing panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results. We also offer microsatellite instability and mismatch repair analysis to help identify patients most likely to benefit from certain therapies.

Non-colorectal gastrointestinal cancers Non-colorectal gastrointestinal cancers
NON-COLORECTAL GASTROINTESTINAL CANCERS

We use next-generation sequencing to assist in detecting variations in the most common genes associated with noncolorectal gastrointestinal cancers.

News and updates

The latest

Dengue Outbreaks and Advancements in Colon Cancer Screening: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.

Learn more
Dengue Outbreaks and Advancements in Colon Cancer Screening: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.

Test identifies Lynch syndrome for targeted cancer monitoring: Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC

Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for patients and their families.

Personal journey shapes unique perspective: Linda Hasadsri, M.D., Ph.D.

Dr. Linda Hasadsri’s firsthand encounter with the genetic tests she’s helped develop has provided rare insight into testing quality and implications, enhancing their ability to advocate for the value of testing and infusing their work with deep empathy.

Colorectal panel provides detailed cancer information

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Which Molecular Tests to Order for Colorectal Cancer

This “Specialty Testing” webinar will describe the utility of microsatellite instability testing in colorectal cancer care and discuss the limitation of various assays used to diagnose microsatellite instability.

Mayo Clinic Laboratory and Pathology Research Roundup: Oct. 16

This week’s Research Roundup highlights the role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy.

Mayo Clinic Laboratory and Pathology Research Roundup: Sept. 18

This week’s Research Roundup highlights Mayo Clinic researchers who conducted a study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic colorectal cancer.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.